Document Detail


Safety and efficacy of stem cell mobilization under imatinib therapy.
MedLine Citation:
PMID:  14555323     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In order to investigate the safety and efficacy of stem cell mobilization in chronic myeloid leukemia patients under imatinib therapy we treated 10 such patients with granulocyte colony-stimulating factor. We observed that none of the patients developed progressive disease under this treatment. Instead, sufficient CD34+ apheresis could be performed in 7 patients and, as assessed by nested reverse transcriptase polymerase chain reaction (RT-PCR), bcr/abl-negative stem cell products could be generated in 3 patients. Interestingly, in 3 other patients with bcr/abl-positivity in 1st round RT-PCR of peripheral leukocytes, bcr/abl transcripts in stem cell products could only be detected by nested RT-PCR.
Authors:
Karl-Anton Kreuzer; Christine Klühs; Michaela Schwarz; Bernd Dörken; Philipp Le Coutre
Related Documents :
15370263 - Acute myeloid leukemia following treatment with cladribine for hairy cell leukemia: a c...
6194073 - Monocytosis as a sign of subsequent leukemia in patients with cytopenias (preleukemia).
8502343 - Bacteremia in patients on chronic hemodialysis. a multicenter prospective survey.
Publication Detail:
Type:  Letter; Review    
Journal Detail:
Title:  Haematologica     Volume:  88     ISSN:  1592-8721     ISO Abbreviation:  Haematologica     Publication Date:  2003 Oct 
Date Detail:
Created Date:  2003-10-13     Completed Date:  2004-09-30     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0417435     Medline TA:  Haematologica     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  1199-200     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / adverse effects,  therapeutic use
Hematopoietic Stem Cell Mobilization / methods*
Humans
Piperazines / adverse effects*,  therapeutic use*
Pyrimidines / adverse effects*,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Incidence and characteristics of myelodysplastic syndromes in Ourense (Spain) between 1994-1998.
Next Document:  Induction of apoptosis by castration in epithelium of the mouse seminal vesicles.